Control strategy could facilitate faster bioburden detection
According to the paper, the control strategy for rapid bioburden testing provides manufacturers with enhanced capabilities for process control.
List view / Grid view
According to the paper, the control strategy for rapid bioburden testing provides manufacturers with enhanced capabilities for process control.
Demand for laboratory automation is a key driving factor for growth of the European laboratory information management system (LIMS) market, research asserts.
Following US FDA approval of Lenmeldy™ (atidarsagene autotemcel) for early-onset metachromatic leukodystrophy (MLD), the US wholesale acquisition cost of the gene therapy has been set to $4.25 million.
The new acquisition is set to boost Lonza’s large-scale biologics manufacturing capacity for mammalian therapeutics.
Research predicts the global continuous bioprocessing market will witness a CAGR of 19.72 percent between 2024-2031.
Novartis’ new acquisition aims to advance first-in-class STING treatments for inflammation-driven diseases.
Research suggests that to prevent common mould growth, low-dose far-UVC light could be applied as a chemical-free addition to manual cleaning of indoor surfaces.
As part of the proposed acquisition, Alexion (AstraZeneca Rare Disease) will add a therapeutic to its pipeline that has potential to “shift the treatment paradigm” in hypoparathyroidism.
Delivering the traditional Parkinson’s treatment via subcutaneous infusion over a 24-hour period was shown to be safe and effective, research found.
Technology innovations and a stronger focus on developing novel drugs to treat chronic diseases, are key drivers for the global mycoplasma testing market up to the next decade, research states.
Combining near-infrared spectroscopy (NIR) hyperspectral imaging (HSI) and machine learning could offer a simpler, non-invasive alternative to established analytical techniques such as chromatography, research suggests.
A novel liver therapy authorised under US Food and Drug Administration (FDA) Accelerated Approval, is a potential game-changer in the NASH treatment space.
The new sterilisation method could provide an affordable, rapid approach for preparing microbiological culture media, research suggests.
A new global collaboration and exclusive option-to-license agreement between Boehringer Ingelheim and Sosei Group Corporation includes a novel precision treatment for schizophrenia.
The first South Korean vaccine manufacturing facility to achieve EU-GMP certification from the European Medicines Agency (EMA) is being expanded to support global supply of a pneumococcal conjugate vaccine.